Dimension Therapeutics, Inc. (NASDAQ:DMTX) has been assigned an average recommendation of “Hold” from the eight ratings firms that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating on the company. The average 1 year target price among brokers that have covered the stock in the last year is $5.08.

DMTX has been the topic of a number of research reports. Canaccord Genuity dropped their price objective on Dimension Therapeutics from $20.00 to $12.00 and set a “buy” rating on the stock in a report on Wednesday, June 28th. Zacks Investment Research downgraded Dimension Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, July 10th. Chardan Capital restated a “hold” rating on shares of Dimension Therapeutics in a report on Monday, August 14th. Citigroup Inc. downgraded Dimension Therapeutics from a “neutral” rating to a “sell” rating and increased their price objective for the stock from $3.41 to $5.50 in a report on Tuesday, September 19th. Finally, ValuEngine upgraded Dimension Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, September 30th.

Dimension Therapeutics (DMTX) opened at 5.95 on Wednesday. The firm’s 50-day moving average is $4.54 and its 200-day moving average is $2.17. Dimension Therapeutics has a 12 month low of $1.05 and a 12 month high of $7.42. The firm’s market capitalization is $149.06 million.

Dimension Therapeutics (NASDAQ:DMTX) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.49) EPS for the quarter, hitting analysts’ consensus estimates of ($0.49). Dimension Therapeutics had a negative return on equity of 98.72% and a negative net margin of 358.21%. The firm had revenue of $4.37 million for the quarter. On average, equities research analysts expect that Dimension Therapeutics will post ($2.10) EPS for the current year.

A number of hedge funds have recently made changes to their positions in DMTX. Two Sigma Securities LLC acquired a new position in Dimension Therapeutics during the first quarter valued at approximately $108,000. Goldman Sachs Group Inc. grew its holdings in Dimension Therapeutics by 206.7% during the second quarter. Goldman Sachs Group Inc. now owns 80,471 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 54,231 shares during the last quarter. Finally, Weiss Multi Strategy Advisers LLC grew its holdings in Dimension Therapeutics by 6.7% during the first quarter. Weiss Multi Strategy Advisers LLC now owns 390,403 shares of the biotechnology company’s stock valued at $683,000 after purchasing an additional 24,489 shares during the last quarter. Institutional investors own 70.75% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Dimension Therapeutics, Inc. (DMTX) Receives Average Recommendation of “Hold” from Analysts” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/10/11/dimension-therapeutics-inc-dmtx-receives-average-recommendation-of-hold-from-analysts.html.

Dimension Therapeutics Company Profile

Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).

Analyst Recommendations for Dimension Therapeutics (NASDAQ:DMTX)

Receive News & Ratings for Dimension Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.